Agios outlines path to profitability and targets $45M-$50M in 2026 PK deficiency revenue as AQVESME U.S. launch progresses
Source: SeekingAlpha
2026-02-12 17:05:18 ET
More on Agios Pharmaceuticals
- Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Agios Pharmaceuticals Q4 2025 Earnings Preview
- FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults
Read the full article on Seeking Alpha
For further details see:
Agios outlines path to profitability and targets $45M-$50M in 2026 PK deficiency revenue as AQVESME U.S. launch progresses
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
3.97% G/L:
$28.005 Last:
208,618 Volume:
$27.53 Open:
AGIO Latest News
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
February 23, 2026 10:57:17 am
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
February 17, 2026 03:58:22 pm
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
